about
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeuticsTargeted therapy using nanotechnology: focus on cancerTargeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approachEngineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.Therapeutic antibodies against cancer.Fibronectin as target for tumor therapy.The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes.Strategies for enhanced photodynamic therapy effects.The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.Factors affecting the clearance and biodistribution of polymeric nanoparticles.HER2-positive male breast cancer: an update.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Delivery systems for in vivo use of nucleic Acid drugs.Antibody Engineering for Pursuing a Healthier FutureE-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.Alternative reagents to antibodies in imaging applications.
P2860
Q27006569-C35F85FD-A0BD-430E-BA3E-62C4CF98683BQ27023361-A4E90CEA-FE45-46D0-B409-C9CBB583FBDBQ28481264-DAF3B7B5-03FC-44CA-96A7-7E793218FABBQ33224048-E4D59822-B111-4934-8FF7-512BE40458B2Q34372166-A7AFDE60-F417-4FB1-A644-0FA986D0269EQ35908498-062743D7-EAAB-45D6-85A9-1B2A304AF328Q36354769-8BBBE27D-538E-4980-80EB-C4E0757BFCD1Q36677504-0A20F790-E3D6-47E8-AE19-5DD4D001F52BQ36735188-C0761FF6-C67E-451F-8F00-8D9D5B91D667Q36945978-8BCBFAA4-5557-4B3F-BF50-21C43905A8EEQ36967905-88093E5E-C1B7-4456-A87D-A73CF9ECBC40Q37146591-96E70F86-6E69-4023-B395-A96EB5BAAABEQ37355586-E783D6D9-1543-4983-AB7E-DA16D9271901Q37815479-E37CF572-4D6E-485F-8545-12C7A7C0FE2EQ37928915-00AF0C80-3C0C-4580-AFA1-A9B6DEB0FCE7Q38731632-A0471225-F27C-4414-92C1-A74607A4B0EDQ39579131-137A0CE2-3F76-44B7-9A41-069B1076A805Q41579389-79D845CB-EB43-40EC-AB8E-4EE1AD88E85B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
New approaches to antibody therapy.
@ast
New approaches to antibody therapy.
@en
New approaches to antibody therapy.
@nl
type
label
New approaches to antibody therapy.
@ast
New approaches to antibody therapy.
@en
New approaches to antibody therapy.
@nl
prefLabel
New approaches to antibody therapy.
@ast
New approaches to antibody therapy.
@en
New approaches to antibody therapy.
@nl
P2860
P356
P1433
P1476
New approaches to antibody therapy.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204000
P407
P577
2000-12-01T00:00:00Z
P5875
P6179
1034934511